Skip to main content
SpringerLink
Log in

Prescription patterns and efficacy of drugs for patients with dementia: physicians’ perspective in Italy

  • Original Articles
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Background and aims: The aim of this study was to assess the prescription practices and judgment of efficacy of physicians of drugs used for the cognitive and non-cognitive symptoms of dementia. Methods: Physicians from 88 Italian Alzheimer Evaluation Units were surveyed by means of a structured questionnaire assessing the proportion of patients with four different types of dementia prescribed with drugs for cognitive and non-cognitive symptoms, and physicians’ perceived efficacy of cholinesterase inhibitors. The Units prescribed cholinesterase inhibitors for 73 patients per year on average. Results: Cholinesterase inhibitors are prescribed to 90% of patients with Alzheimer’s disease (AD), 80% with with Lewy body dementia (LBD), and 35–45% with vascular dementia (VD) and frontotemporal lobar degeneration (FTLD). Selective serotonin uptake inhibitors (SSRIs) are prescribed for 28–45% of patients with all dementias except LBD (16%). Atypical neuroleptics were prescribed for 23–31% of patients, with no difference across types of dementia. Other drugs, such as ginkgo and nootropics, were prescribed less frequently, except in VD (20%). The perceived efficacy on cognitive and non-cognitive symptoms, assessed on a 0-to-10 ordinal scale, was highest in AD (4.3–6.1), intermediate in LBD (3.5–5.3) and VD (3.3–4.7), and lowest in FTLD (2.0–2.7). Conclusions: The data indicate that, in specialized Italian centers, cholinesterase inhibitors and atypical neuroleptics are largely used in patients with AD and LBD, but the former are prescribed off-label to a remarkable proportion of patients with VD and FTLD. The efficacy of cholinesterase inhibitors is perceived to be highest in AD and poorest in FTLD. Perceived efficacy is affected more by whom is treated than by what is used.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Evans JG, Wilcock G, Birks J. Evidence-based pharmacotherapy of Alzheimer’s disease. Int J Neuropsychopharmacol 2004; 7: 351–69.

    Article  PubMed  CAS  Google Scholar 

  2. Mayeux R, Sano M. Treatment of Alzheimer’s Disease. N Engl J Med 1999; 341: 1670–9.

    Article  PubMed  CAS  Google Scholar 

  3. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105–15.

    Article  PubMed  CAS  Google Scholar 

  4. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ 2005; 331: 321–7.

    Article  PubMed  CAS  Google Scholar 

  5. Kmietowicz Z. NICE proposes to withdraw Alzheimer’s drugs from NHS. BMJ 2005; 330: 495.

    Article  PubMed  Google Scholar 

  6. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002; 288: 1475–83.

    Article  PubMed  Google Scholar 

  7. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329: 75.

    Article  PubMed  Google Scholar 

  8. Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer’s disease. Am J Psychiatry 1998; 155: 1512–20.

    PubMed  CAS  Google Scholar 

  9. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946–55.

    Article  PubMed  Google Scholar 

  10. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26: 494–504.

    Article  PubMed  CAS  Google Scholar 

  11. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIAD. Arch Gen Psychiatry 2003; 60: 737–46.

    Article  PubMed  CAS  Google Scholar 

  12. Finkel SI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer’s disease. Clin Ther 2004; 26: 980–90.

    Article  PubMed  CAS  Google Scholar 

  13. Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1997; 9: 591–3.

    PubMed  CAS  Google Scholar 

  14. Teri L, Logsdon RG, Peskind E, et al. Alzheimer’s Disease Cooperative Study. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55:1271–8. Erratum in: Neurology 2001; 56: 426.

    Article  PubMed  CAS  Google Scholar 

  15. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214–9.

    Article  PubMed  CAS  Google Scholar 

  16. Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–8.

    PubMed  Google Scholar 

  17. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology 1998; 50: 1222–30.

    Article  PubMed  CAS  Google Scholar 

  18. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998; 50: 136–45.

    CAS  Google Scholar 

  19. Mega MS, Masterman DM, O’Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999; 56: 1388–93.

    Article  PubMed  CAS  Google Scholar 

  20. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebocontrolled international study. Lancet 2000; 356: 2031–6.

    Article  PubMed  CAS  Google Scholar 

  21. Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002; 13: 183–92.

    Article  PubMed  CAS  Google Scholar 

  22. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283–90.

    Article  PubMed  Google Scholar 

  23. Black S, Roman GC, Geldmacher DS, et al. Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323–30.

    Article  PubMed  CAS  Google Scholar 

  24. Wilkinson D, Doody R, Helme R, et al. Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebocontrolled study. Neurology 2003; 61: 479–86.

    CAS  Google Scholar 

  25. Ministerodellasalute-Medicinali e vigilanza-Informazione sui farmaci [Ministero della salute web site]. November 2, 2005. Available at: www.alzheimer-cronos.it http://www.ministerosalute.it/imgs/C_17_notaInf_1_listaFile_itemName_0_file.pdf /imgs/C_17_notaInf_1_listaFile_itemName_0_file.pdf; http://www.ministerosalute.it/imgs/C_17_notaInf_1_listaFile_itemName_1_file.pdf./imgs/C_17_notaInf_1_listaFile_itemName_1_file.pdf.; Accessed May 5, 2006.

  26. Frisoni GB: Centro Alzheimer [Centro Alzheimer web site]. October 29, 2005. Available at: http://www.centroalzheimer.it/ricuva.htm; Accessed July 24, 2006.

  27. Frisoni GB, Canu E, Geroldi C, Zanetti O, Zacchi V. Drug prescription in mild cognitive impairment: the physicians’ perspective in Italy. Int J Geriatr Psychiatry 2006; 21: 1071–7.

    Article  PubMed  Google Scholar 

  28. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–8.

    Article  PubMed  CAS  Google Scholar 

  29. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269–76.

    CAS  Google Scholar 

  30. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc. 2001; 49: 1590–9.

    Article  PubMed  CAS  Google Scholar 

  31. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–8.

    CAS  Google Scholar 

  32. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293–303.

    CAS  Google Scholar 

  33. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease — results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237–44.

    Article  PubMed  CAS  Google Scholar 

  34. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–20. Erratum in: Neurology 2001; 57: 2153.

    Article  PubMed  CAS  Google Scholar 

  35. Suh GH, Yeon Jung H, Uk Lee C, et al. Korean Galantamine Study Group. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer’s disease in a Korean population. Clin Ther 2004; 26: 1608–18.

    CAS  Google Scholar 

  36. Seltzer B, Zolnouni P, Nunez M, et al. Donepezil “402” Study Group. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004; 61: 1852–6.

    Google Scholar 

  37. Karaman Y, Erdogan F, Koseoglu E, Turan T, Ersoy AO. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 19: 51–6.

    Article  PubMed  CAS  Google Scholar 

  38. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 2004; 21: 931–7.

    Article  PubMed  CAS  Google Scholar 

  39. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002; (4):CD003120.

  40. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2004; (2): CD000269.

  41. Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev 2003; (2): CD003158.

  42. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev2003; (1): CD003119.

  43. Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001; (4): CD003159.

  44. Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2001; (2): CD001011.

  45. Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia. Cochrane Database Syst Rev 2001; (2): CD000359.

  46. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004; 351: 1885–90.

    Article  PubMed  CAS  Google Scholar 

  47. Tenery RM. Interactions between physicians and the health care technology industry. JAMA 2000; 283: 391–3.

    Article  PubMed  Google Scholar 

  48. Editorial. Drug-company influence on medical education in USA. Lancet 2000; 356: 781.

    Article  Google Scholar 

  49. Mulrow CD, Cook DJ, Davidoff F. Systematic reviews: critical links in the great chain of evidence. Ann Intern Med 1997; 126: 389–91.

    Article  PubMed  CAS  Google Scholar 

  50. Tariot PN, Profenno LA, Ismail MS. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry 2004;65(Suppl 11):11–5.

    PubMed  CAS  Google Scholar 

  51. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293: 596–608.

    Article  PubMed  CAS  Google Scholar 

  52. Tamblyn R, Abrahamowicz M, du Berger R, McLeod P, Bartlett G. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005; 53: 233–41.

    Article  PubMed  Google Scholar 

  53. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med 2004; 164: 1567–72.

    Google Scholar 

  54. Hemmelgarn B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997; 278: 27–31.

    Article  PubMed  CAS  Google Scholar 

  55. Foy A, O’Connell D, Henry D, Kelly J, Cocking S, Halliday J. Benzodiazepine use as a cause of cognitive impairment in elderly hospital inpatients. J Gerontol A Biol Sci Med Sci 1995; 50: M99–106.

    Article  PubMed  CAS  Google Scholar 

  56. Shorr RI, Robin DW. Rational use of benzodiazepines in the elderly. Drugs Aging 1994; 4: 9–20.

    Article  PubMed  CAS  Google Scholar 

  57. Galinsky DE. Caution on use of benzodiazepines in the elderly. N Engl J Med 1979; 300: 1054–5.

    Article  PubMed  CAS  Google Scholar 

  58. Frisoni GB. Diagnosi e Terapia della malattia di Alzheimer: Un percorso per le Unità di Valutazione Alzheimer. Ed. Fatebenefratelli, 2004.

  59. Bellelli G, Lucchi E, Minicuci N, et al. Results of a multi-level therapeutic approach for Alzheimer’s disease subjects in the “real world” (CRONOS project): a 36-week follow-up study. Aging Clin Exp Res 2005; 17: 54–61.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Epidemiology Neuroimaging & Telemedicine, Rome

    Giovanni B. Frisoni MD, Elisa Canu, Cristina Geroldi, Barbara Brignoli, Livio Anglani & Samantha Galluzzi

  2. Psychogeriatric Ward, IRCCS San Giovanni di Dio — FBF, Via Pilastroni 4, 25125, Brescia, Italy

    Giovanni B. Frisoni MD & Cristina Geroldi

  3. AFaR Associazione Fatebenefratelli per la Ricerca, Rome

    Giovanni B. Frisoni MD

  4. Medical Service Office, Rome

    Valeria Zacchi

  5. Alzheimer’s Unit, IRCCS Centro San Giovanni di Dio — FBF, Brescia, Italy

    Orazio Zanetti

Authors
  1. Giovanni B. Frisoni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisa Canu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristina Geroldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barbara Brignoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Livio Anglani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Samantha Galluzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Valeria Zacchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Orazio Zanetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni B. Frisoni MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frisoni, G.B., Canu, E., Geroldi, C. et al. Prescription patterns and efficacy of drugs for patients with dementia: physicians’ perspective in Italy. Aging Clin Exp Res 19, 349–355 (2007). https://doi.org/10.1007/BF03324714

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03324714

Keywords

Search

Navigation